Skip to main content

Advertisement

Log in

Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Data on LA/LAA thrombus resolution after rivaroxaban treatment has not been established. The aim of the present study was to compare the efficacy and safety on the resolution of LA/LAA thrombus between rivaroxaban and warfarin in nonvalvular atrial fibrillation (AF) patients. 80 AF patients with LA/LAA thrombus between January 2013 and June 2016 were randomized divided into warfarin group (n = 40) and rivaroxaban group (n = 40). Compared to warfarin group, thrombin time (TT; p < 0.0001), plasma prothrombin time (PT; p < 0.0001), and activated partial thromboplastin time (APTT; p = 0.0019) were significantly lower, and fibrinogen (FIB; p < 0.0001) was significantly higher in rivaroxaban group. TEE shown the average length (p < 0.0001), average width (p = 0.0008) and average area (p < 0.0001) of thrombus were significantly lower in rivaroxaban group compared to warfarin group after 6-week treatments. No major or fatal bleeding and ischemic stroke occurred in both two groups. The 20 mg dose Rivaroxaban is more effective than warfarin on the resolution of LA/LAA thrombus in nonvalvular AF patients especially after 6-week treatments. The results suggest that rivaroxaban is a potential option for the treatment of LA/LAA thrombus in patients with nonvalvular AF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Al-Saady NM, Obel OO, Camm AJ (1999) Left atrial appendage: structure, function, and role in thromboembolism. Heart 5(82):547–554

    Article  Google Scholar 

  2. Saeed M, Rahman A, Afzal A (2006) Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation. Int J Cardiol 3(113):401–405

    Article  Google Scholar 

  3. Thambidorai SK, Murray RD, Parakh K, ACUTE Investigators (2005) Utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Am J Cardiol 7(96):935–941

    Article  Google Scholar 

  4. Birman-Deych E, Radford MJ, Nilasena DS (2006) Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation. Stroke 4(37):1070–1074

    Article  CAS  Google Scholar 

  5. Aryal MR, Pandit A, Karmacharya P (2014) Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 4(114):577–582

    Article  CAS  Google Scholar 

  6. Uda Y, Phan TD, Kistler PM (2016) Persistent left atrial thrombus on treatment with rivaroxaban and subsequent resolution after warfarin therapy. Intern Med J 7(46):855–856

    Article  Google Scholar 

  7. Stepanyan G, Badhwar N, Lee RJ (2014) Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electrophysiol 1(40):33–38

    Article  Google Scholar 

  8. Lakkireddy D, Reddy YM, Di Biase L (2014) Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 10(63):982–988

    Article  CAS  Google Scholar 

  9. Hammerstingl C, Pötzsch B, Nickenig G (2013) Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost 4(109):583–584

    Google Scholar 

  10. Eitel C, Koch J, Sommer P (2013) Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 11(15):1587–1593

    Article  Google Scholar 

  11. Conway DS, Buggins P, Hughes E (2004) Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 11(43):2075–2082

    Article  CAS  Google Scholar 

  12. Roldán V, Marín F, Blann AD (2003) Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 14(24):1373–1380

    Article  CAS  Google Scholar 

  13. Vene N, Mavri A, Kosmelj K (2003) High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 6(90):1163–1172

    Google Scholar 

  14. Nagarakanti R, Ezekowitz MD, Oldgren J (2011) Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2(123):131–136

    Article  CAS  Google Scholar 

  15. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 12(146):857–867

    Article  Google Scholar 

  16. Go AS, Hylek EM, Borowsky LH (1999) Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 12(131):927–934

    Article  Google Scholar 

  17. Lip GY, Hammerstingl C, Marin F (2015) Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J 4(169):464–471

    Article  CAS  Google Scholar 

  18. Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 12(361):1139–1151

    Article  Google Scholar 

  19. Patel MR, Mahaffey KW, Garg J, ROCKET AF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 10(365):883–891

    Article  Google Scholar 

  20. Camm AJ, Amarenco P, Haas S, XANTUS Investigators (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 14(37):1145–1153

    Article  Google Scholar 

  21. Lip GY, Hammerstingl C, Marin F, X-TRA Study and CLOT-AF Investigators (2016) Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J 2016(178):126–134

    Article  Google Scholar 

  22. Varin R, Mirshahi S, Mirshahi P (2013) Whole blood clots are more resistant to lysis than plasma clots–greater efficacy of rivaroxaban. Thromb Res 3(131):e100–e109

    Article  CAS  Google Scholar 

  23. Miwa Y, Minamishima T, Sato T (2016) Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban. J Arrhythm 3(32):233–235

    Article  Google Scholar 

  24. Silaruks S, Thinkhamrop B, Kiatchoosakun S (2004) Resolution of left atrial thrombus after 6 months of anticoagulation in candidates for percutaneous transvenous mitral commissurotomy. Ann Intern Med 2(140):101–105

    Article  Google Scholar 

Download references

Funding

This study was supported by the General Program of Natural Science Foundation of Guangxi Province of China (Grant No. 2017GXNSFAA198129) and the Key Project of Scientific Research and Technology Development of Qingxiu District of Nanning, Guangxi government (Grant No. 2017027).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jin-yi Li.

Ethics declarations

Conflict of interest

The author declares that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ke, Hh., He, Y., Lv, Xw. et al. Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients. J Thromb Thrombolysis 48, 270–276 (2019). https://doi.org/10.1007/s11239-019-01876-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-019-01876-z

Keywords

Navigation